NEW YORK, Oct. 19 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Colorectal Cancer Drug Futures
http://www.reportlinker.com/p0315765/Colorectal-Cancer-Drug-Futures.html
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED
Espicom's Colorectal Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document.
24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom's research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.
Early-stage colorectal cancer (CRC) is generally treated with surgery and radiation....
....with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found at this early stage, and, as a result, there remains considerable unmet clinical need within the CRC market.
For those patients who experience recurrence following surgery there is a clear need for effective therapies earlier in the course of the disease. In addition, with around 76% of patients (Stages II-IV) eligible for chemotherapy, new formulations which improve patients' quality of life and increase survival are sorely needed.
In 2008, the CRC drug market (US, EU and Japan) for major branded therapies was valued at just over US$8 billion. Whilst chemotherapy is the mainstay of CRC treatment the use of targeted therapies are gaining acceptance in the treatment of advanced disease. This trend is expected to continue as new combinations are evaluated and therapies are increasingly used in the adjuvant setting to address the unmet clinical needs within the market. Indeed, by 2015 targeted therapies will account for 77% of the CRC market.
Which products and companies will benefit from this trend?
NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER
This all new web service from Espicom, Colorectal Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.
WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
Track the drug's progress and stay abreast of developments
Understand the drug's novelty and mode of action
Evaluate the strength of the company developing/producing the drug
Review opportunities and challenges with Espicom's unique 5-point competitive assessment
Know the launch timeframe for new products or indications
Be aware of promising mid-stage development candidates
Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS
For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
Novelty/rationale for mechanism of action
Current status
Proof of concept/clinical data
Development risks
Company expertise
Competition within the market-place
Sales forecast (for key late-stage and launched products)
Competitor ratio analysis score
Clinical trial results
50 CRC ACTIVE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.
Approved
Bevacizumab
Capecitabine
Cetuximab
Doxifluridine
Irinotecan
Oxaliplatin
Panitumumab
Phase III
Aflibercept
Brivanib
Cediranib
HA-irinotecan
OncoVAX
Perifosine
Regorafenib
Talaporfin sodium
Phase II/III
Canfosfamide
Phase II
Adecatumumab
Angiocept
Arenegyr
AZD6244
BIBF 1120
Cixutumumab
Conatumumab
CPX-1
CS-7017
Davanat
Enzastaurin
Figitumumab
GDC-0449
Gimatecan
Linifanib
Mapatumumab
Necitumumab
Pemetrexed disodium
Picoplatin
Ramucirumab
RG 7204
SAR109659
Sorafenib
Sunitinib
TAS-102
Telatinib
Tigatuzumab
Phase I/II
ARQ 197
EMD525797
Phase I
184072
Dulanermin
IMO-2055
Interleukin-21
Pazopanib
Tivozanib
Discontinued
ABT-751
GDC-0449
PD-325901
Trastuzumab
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS
Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years' of archive material.
Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.
With Espicom's Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.
BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!
4D Research is Espicom's tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom's leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.
Table of Contents
OVERVIEW ... 1
PHASE I... 3
184072 .. 3
Current Status ... 3
DULANERMIN .... 4
Mode of Action .. 4
Current Status ... 4
Proof of Concept ..... 4
Development Risks .. 4
Company Expertise .. 4
Competition Within the Market-place ..... 5
Competitor Ratio Analysis .... 5
Clinical Trial Results .. 5
IMO-2055 ..... 6
Mode of Action .. 6
Current Status ... 6
Proof of Concept/Clinical Data ... 6
Company Expertise .. 7
Clinical Trial Results . 7
INTERLEUKIN-21 .... 8
Mode of Action .. 8
Current Status ... 8
Proof of Concept/Clinical Data ... 9
Development Risks .. 9
Company Expertise .. 9
Competition within the Market-place ...10
Competitor Ratio Analysis ..10
Clinical Trial Results 10
PAZOPANIB 12
Mode of Action 12
Current Status .12
Proof of Concept/Clinical Data .14
Development Risks .14
Company Expertise .15
Competition within the Market-place ...15
Data Exclusivity .....16
Patent Expiry ...16
Competitor Ratio Analysis ..16
Forecast ...17
Clinical Trial Results .....18
TIVOZANIB 20
Mode of Action 20
Current Status .20
Proof of Concept/Clinical Data .20
Development Risks .21
Company Expertise .21
Competition within the Market-place ...22
Competitor Ratio Analysis ..22
Forecast ...23
PHASE I/II .. 24
ARQ 197 ..... 24
Mode of Action 24
Current Status .24
Proof of Concept/Clinical Data .24
Development Risks .25
Company Expertise .25
Competition within the Market-place ...26
Competitor Ratio Analysis ..26
Clinical Trial Results 26
EMD 525797 .... 29
Mode of Action 29
Current Status .29
PHASE II ..... 30
ADECATUMUMAB .. 30
Mode of Action 30
Current Status .30
Proof of Concept/Clinical Data .30
Development Risks .32
Company Expertise .32
Competition within the Market-place ...32
Clinical Trial Results .....33
ANGIOCEPT 35
Mode of Action 35
Current Status .35
Proof of Concept/Clinical Data .35
Development Risks .35
Company Expertise .35
Competition within the Market-place ...36
Competitor Ratio Analysis ..36
ARENEGYR . 37
Mode of Action 37
Current Status .37
Proof of Concept/Clinical Data .38
Development Risks .39
Company Expertise .39
Competition within the Market-place ...40
Competitor Ratio Analysis ..41
AZD6244.... 42
Mode of Action 42
Current Status .42
Clinical Trial Results 42
BIBF 1120 .....44
Mode of Action 44
Current Status .44
Proof of Concept/Clinical Data .45
Development Risks .45
Company Expertise .45
Competition Within the Market-place ...46
Competitor Ratio Analysis ..46
Forecast ...47
Clinical Trial Results 47
CIXUTUMUMAB ..... 49
Mode of Action 49
Current Status .49
Proof of Concept/Clinical Data .50
Development Risks .50
Company Expertise .50
Competition within the Market-place ...50
Competitor Ratio Analysis ..50
CONATUMUMAB .... 52
Mode of Action 52
Current Status .52
Proof of Concept ...52
Development Risks .52
Company Expertise .52
Competition Within the Market-place ...53
Competitor Ratio Analysis ..53
CPX-1 ... 54
Mode of Action 54
Current Status .54
Proof of Concept/Clinical Data .54
Development Risks .55
Company Expertise .55
Competition within the Market-place ...55
Competitor Ratio Analysis ..55
CS-7017 56
Mode of Action 56
Current Status .56
DAVANAT .... 57
Mode of Action 57
Current Status .57
Proof of Concept/Clinical Data .57
Development Risks .58
Company Expertise .58
Competition within the Market-place ...58
Competitor Ratio Analysis ..59
ENZASTAURIN . 60
Mode of Action 60
Current Status .60
Proof of Concept/Clinical Data .60
Development Risks .62
Company Expertise .62
Competition within the Market-place ...62
Competitor Ratio Analysis ..63
Forecast ...63
Clinical Trial Results .....64
FIGITUMUMAB 65
Mode of Action 65
Current Status .65
Proof of Concept ...65
Development Risks .66
Company Expertise .66
Competition Within the Market-place ...66
Competitor Ratio Analysis ..67
Clinical Trial Results 68
GDC-0449 ... 69
Mode of Action 69
Current Status .69
Proof of Concept/Clinical Data .69
Development Risks .70
Company Expertise .70
Competition within the Market-place ...71
Competitor Ratio Analysis ..71
Clinical Trial Results 71
GIMATECAN ..... 73
Mode of Action 73
Proof of Concept/Clinical Data .73
LINIFANIB . 74
Mode of Action 74
Current Status .74
Proof of Concept/Clinical Data .74
Development Risks .75
Company Expertise .75
Competition within the Market-place ...75
Competitor Ratio Analysis ..76
MAPATUMUMAB .... 77
Mode of Action 77
Current Status .78
Proof of Concept ...78
Development Risks .78
Company Expertise .79
Competition Within the Market-place ...79
Competitor Ratio Analysis ..79
Forecast ...79
Clinical Trial Results 79
NECITUMUMAB ..... 81
Mode of Action 81
Current Status .81
Proof of Concept/Clinical Data .81
Development Risks .81
Company Expertise .82
Competition within the Market-place ...82
Competitor Ratio Analysis ..83
PEMETREXED DISODIUM 84
Mode of Action 84
Current Status .84
Proof of Concept/Clinical Data .85
Development Risks .86
Company Expertise .86
Competition within the Market-place ...86
Data Exclusivity .....87
Patent Expiry ...87
Generic Competition .....87
Competitor Ratio Analysis ..87
Forecast ...88
Clinical Trial Results 88
Metastatic Breast Cancer ....89
PICOPLATIN .... 90
Mode of Action 90
Current Status .90
Proof of Concept/Clinical Data .90
Development Risks .91
Company Expertise .91
Competition within the Market-place ...92
Patent Expiry ...92
Competitor Ratio Analysis ..93
RAMUCIRUMAB ..... 94
Mode of Action 94
Current Status .94
Proof of Concept/Clinical Data .94
Development Risks .94
Company Expertise .95
Competition within the Market-place ...95
Competitor Ratio Analysis ..95
Forecast ...96
RG7204 . 97
Mode of Action 97
Current Status .97
Proof of Concept ...97
Clinical Trial Results 98
SAR109659 .... 100
Mode of Action ....100
Current Status .....100
Proof of Concept/Clinical Data .....100
Development Risks .....101
Company Expertise .....101
Competition within the Market-place .101
Competitor Ratio Analysis 101
Clinical Trial Results ....102
SORAFENIB .... 104
Mode of Action ....104
Current Status .....105
Proof of Concept/Clinical Data .....106
Development Risks .....107
Company Expertise .....107
Competition within the Market-place .108
Data Exclusivity ...108
Patent Expiry .109
Competitor Ratio Analysis 110
Forecast .110
Clinical Trial Results ....112
SUNITINIB MALATE . 113
Mode of Action ....113
Current Status .....114
Proof of Concept/Clinical Data .....115
Development Risks .....116
Company Expertise .....117
Competition within the Market-place .117
Data Exclusivity ...118
Patent Expiry .118
Generic Competition ...118
Competitor Ratio Analysis 118
Forecast .120
Clinical Trial Results ....122
TAS-102 .... 125
Mode of Action ....125
Current Status .....125
TELATINIB ..... 126
Current Status .....126
Proof of Concept/Clinical Data .....126
Development Risks .....126
Company Expertise .....126
Competition within the Market-place .127
Competitor Ratio Analysis 127
TIGATUZUMAB .... 128
Mode of Action ....128
Current Status .....128
PHASE II/III ... 129
CANFOSFAMIDE .. 129
Mode of Action ....129
Current Status .....129
Proof of Concept/Clinical Data .....129
Development Risks .....130
Company Expertise .....130
Competition within the Market-place .130
Competitor Ratio Analysis 132
PHASE III . 133
AFLIBERCEPT 133
Mode of Action ....133
Current Status .....133
Proof of Concept/Clinical Data .....133
Development Risks .....135
Company Expertise .....136
Competition within the Market-place .136
Competitor Ratio Analysis 137
Forecast .137
Clinical Trial Results ....139
BRIVANIB 141
Mode of Action ....141
Current Status .....141
Proof of Concept/Clinical Data .....141
Development Risks .....142
Company Expertise .....142
Competition within the Market-place .142
Competitor Ratio Analysis 144
Forecast .144
ERLOTINIB ..... 147
Mode of Action ....147
Current Status .....147
Proof of Concept/Clinical Data .....148
Development Risks .....150
Company Expertise .....151
Competition within the Market-place .151
Data Exclusivity ...152
Patent Expiry .152
Generic Competition ...153
Competitor Ratio Analysis 153
Forecast .153
Clinical Trial Results ....154
HA-IRINOTECAN . 157
Mode of Action ....157
Current Status .....157
Proof of Concept/Clinical Data .....157
Development Risks .....158
Company Expertise .....158
Competition within the Market-place .159
Competitor Ratio Analysis 159
ONCOVAX . 160
Mode of Action ....160
Current Status .....160
Proof of Concept/Clinical Data .....160
Development Risks .....161
Company Expertise .....161
Competition within the Market-place .162
Competitor Ratio Analysis 163
Forecast .164
PERIFOSINE .. 166
Mode of Action ....166
Current Status .....167
Proof of Concept/Clinical Data .....167
Development/Commercialisation Risks ....168
Company Expertise .....168
Competition within the Market-place .169
Competitor Ratio Analysis 169
Forecast .169
REGORAFENIB ..... 170
Mode of Action ....170
Current Status .....170
Proof of Concept/Clinical Data .....170
Development Risks .....171
Company Expertise .....171
Competition within the Market-place .171
Competitor Ratio Analysis 171
Clinical Trial Results ....173
TALAPORFIN SODIUM .... 174
Mode of Action ....174
Current Status .....174
Proof of Concept/Clinical Data .....174
Development Risks .....175
Company Expertise .....175
Competition within the Market-place .175
Competitor Ratio Analysis 176
Forecast .176
Clinical Trial Results ....177
LAUNCHED PRODUCTS 178
BEVACIZUMAB ..... 178
Mode of Action ....178
Current Status .....179
Proof of Concept/Clinical Data .....182
Development Risks .....186
Company Expertise .....187
Competition within the Market-place .187
Competitor Ratio Analysis 189
Forecast .189
Clinical Trial Results ...194
CAPECITABINE .... 198
Mode of Action ....198
Current Status .....198
Proof of Concept/Clinical Data .....200
Development Risks .....202
Company Expertise .....202
Competition within the Market-place .203
Patent Expiry .203
Competitor Ratio Analysis 203
Forecast .205
Clinical Trial Results ....207
CETUXIMAB ... 210
Mode of Action ....210
Current Status .....210
Proof of Concept/Clinical Data .....211
Development Risks .....213
Company Expertise .....213
Competition within the Market-place .214
Generic Competition ...215
Competitor Ratio Analysis 215
Forecast .215
Clinical Trial Results ...216
DOXIFLURIDINE . 221
Mode of Action ....221
Current Status .....221
IRINOTECAN .. 222
Mode of Action ....222
Current Status .....222
Proof of Concept/Clinical Data .....222
Development Risks .....223
Company Expertise .....223
Competition within the Market-place .223
Patent Expiry .224
Generic Competition ...224
Competitor Ratio Analysis 225
Forecast .226
OXALIPLATIN 228
Mode of Action ....228
Current Status .....228
Proof of Concept/Clinical Data .....229
Development Risks .....229
Company Expertise .....230
Competition within the Market-place .230
Patent Expiry .231
Generic Competition ...231
Competitor Ratio Analysis 232
Forecast .232
PANITUMUMAB ... 234
Mode of Action ....234
Current Status .....235
Proof of Concept/Clinical Data .....236
Development Risks .....238
Company Expertise .....238
Competition within the Market-place .239
Competitor Ratio Analysis 239
Forecast ...240
Clinical Trial Results ...241
TEGAFUR+GIMERACIL+OTERACIL 244
Mode of Action ....244
Current Status .....244
Company Expertise .....244
TEGAFUR+URACIL .... 245
Current Status .....245
Company Expertise .....245
Clinical Trial Results ...245
DEVELOPMENT DISCONTINUED ... 247
ABT-751 .... 247
Mode of Action ....247
Current Status .....247
CEDIRANIB .... 248
Current Status .....248
Proof of Concept/Clinical Data .....249
Development Risks .....249
Company Expertise .....249
Competition Within the Market-place .250
Competitor Ratio Analysis 251
Forecast .251
Clinical Trial Results ....253
PD-325901 ..... 255
Mode of Action ....255
Current Status .....255
Proof of Concept/Clinical Data .....255
TRASTUZUMAB .... 256
Mode of Action ....256
Current Status .....257
Proof of Concept/Clinical Data .....260
Development Risks .....261
Company Expertise .....262
Competition within the Market-place .262
Patent Expiry .263
Competitor Ratio Analysis 263
Forecast .264
Clinical Trial Results ....265
METHODOLOGY ... 268
To order this report:
Drug and Medication Industry: Colorectal Cancer Drug Futures
Drug and Medication Business News
Check our Company Profile, SWOT and Revenue Analysis!
Contact Nicolas Bombourg |
|
Reportlinker |
|
Email: [email protected] |
|
US: (805)652-2626 |
|
Intl: +1 805-652-2626 |
|
SOURCE Reportlinker
Share this article